How would you approach a BRAF negative metastatic melanoma patient on immune checkpoint inhibitor therapy with enlarging, symptomatic brain lesions that had previously been treated with SRS?

If on pembrolizumab or nivolumab, when would you escalate to ipilimumab/nivolumab?

Answer from: Medical Oncologist at Academic Institution

Depending on the PS and medical history of the patient, would recommend moving them to ipi (3 mg/kg)/nivo (1 mg/kg) as soon as possible. - Brent Hanks

Comments

Medical Oncologist at Hematology Oncology Medical Group of Orange County
Could it be a radiation necrosis? If this is the o...

Medical Oncologist at Florida Cancer Specialists and Research Institute
Would single agent ipi be ok given that the progre...

Please select the option that best describes you:

How would you approach a BRAF negative metastatic melanoma patient on immune checkpoint inhibitor therapy with enlarging, symptomatic brain lesions that had previously been treated with SRS?

Related Questions